| References |
|
|
Breitburd F,
Kirnbauer R,
Hubbert NL et al.
(1995)
Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
Journal of Virology
69:
3959–3963.
|
|
|
Chan SY,
Delius H and
Halpern AL
(1995)
Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny and taxonomy.
Journal of Virology
69:
3074–3083.
|
|
|
Derkay CS
(1995)
Task force on recurrent respiratory papillomas. A preliminary report. Archives of Otolaryngology.
Head and Neck Surgery
121(12):
1386–1391.
|
|
|
FUTURE II Study Group
(2007a)
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
New England Journal of Medicine
356(19):
1915–1927.
|
|
|
FUTURE II Study Group
(2007b)
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
Journal of Infectious Disease
196:
1438–1446.
|
|
|
Garland SM,
Hernandez-Avila M,
Wheeler CM et al.
(2007)
Females united to unilaterally reduce endo/ectocervical disease (FUTURE) I investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
New England Journal of Medicine
356(19):
1928–1943.
|
|
|
book
Howley PM and
Lowy DR
(2007)
"Papillomaviruses".
In: Knipe DM and
Howley PM (eds)
Fields Virology,
5th ed,
pp. 2300–2354.
Philadelphia: Lippincott, Williams and Wilkins.
|
|
|
Kirnbauer R,
Booy F,
Cheng N,
Lowy DR and
Schiller JT
(1992)
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
Proceedings of the National Academy of Sciences of the USA
89:
12180–12184.
|
|
|
Kirnbauer R,
Chandrachud L,
O'Neil B et al.
(1996)
Virus-like particles of Bovine Papillomavirus type 4 in prophylactic and therapeutic immunization.
Virology
219:
37–44.
|
|
|
Koutsky LA,
Galloway DA and
Holmes KK
(1988)
Epidemiology of genital human papillomavirus infection.
Epidemiological Reviews
10:
122–163.
|
|
|
Lacey CJ
(2005)
Therapy for genital human papillomavirus related disease.
Journal of Clinical Virology
32(suppl 1):
S82–S90.
|
|
|
Lacey CJN,
Lowndes CM and
Shah K
(2006)
Burden and management of non-cancerous HPV related conditions: HPV-6/11 disease.
Vaccine
24S3:
S3/35–S3/41.
|
|
|
Munoz N,
Bosch FX,
Castellsague X et al.
(2004)
Against which HPV vaccine types shall we vaccinate and screen?
International Journal of Cancer
111(2):
278–285.
|
|
|
Paavonen J,
Jenkins D,
Bosch FX et al.
(2007)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Lancet
370(9596):
1414.
|
|
|
Parkin DM and
Bray F
(2006)
The burden of HPV-related cancers.
Vaccine
24S3:
S3/11–S3/25.
|
|
|
Pastrana DV,
Buck CB,
Pang YY et al.
(2004)
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Virology
321(2):
205–216.
|
|
|
Roden RBS,
Greenstone HL,
Kirnbauer R et al.
(1996)
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
Journal of Virology
70:
5875–5883.
|
|
|
Schiller JT,
Castellsagué X,
Villa LL and
Hildesheim A
(2008)
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Vaccine
26(suppl 10):
K53–K61.
|
|
|
Smith LH,
Foster C,
Hitchcock ME et al.
(1995)
Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro.
Journal of Investigative Dermatology
105:
438–444.
|
|
|
Stern PL
(2005)
Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.
Journal of Clinical Virology
32(suppl 1):
S72–S81.
|
|
|
Suzich JA,
Ghim S,
Palmer-Hill FJ et al.
(1995)
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
Proceedings of the National Academy of Sciences of the USA
92:
11553–11557.
|
|
|
Zhou J,
Sun XY,
Stenzel DJ and
Frazer IH
(1991)
Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.
Virology
185:
251–257.
|
|
|
Zimet GD,
Liddon N,
Rosenthal SL,
Lazcano-Ponce E and
Allen B
(2006)
Psychosocial aspects of vaccine acceptability.
Vaccine
24S3:
S3/201–S3/209.
|
|
|
Zur Hausen H,
Meinhof W,
Scheiber W and
Bornkamm GW
(1974)
Attempts to detect virus specific DNA in human tumours. I Nucleic acid hybridizations with complementary RNA of human wart virus.
International Journal of Cancer
13(5):
650–656.
|
| Further Reading |
|
|
other
Castellsague X, de Sanjose S, Aguado T et al. (eds)
(2007)
HPV and cervical cancer in the world: 2007 report.
Vaccine
25 (suppl 3): C1–C230.
|
|
|
other
Franco EL and Drummond MF (eds)
(2008)
Health economics of HPV vaccination for cervical cancer prevention: historical developments and practical applications.
Vaccine
26 (suppl 5): F1–F58.
|
|
|
Markowitz LE,
Dunn EF and
Saraiya M.
(2007)
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP),
vol. 56(RR02),
pp. 1–24.
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm
|
|
|
book
Stern PL and
Kitchener HC (eds)
(2008)
Vaccines for the Prevention of Cervical Cancer (Oxford Oncology Library),
Paperback: 170pp.
Oxford: Oxford University Press.
|
|
|
ePath
WHO/ICO
(2009)
Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer;
http://www.who.int/hpvcentre/en/
|
